VK2735, a dual agonist targeting GLP-1 and GIP receptors, is being evaluated for weight management in obese and overweight adults with comorbid conditions. The obesity treatment market is rapidly expanding, driven by increasing prevalence rates and demand for effective therapies. VK2735's unique mechanism may provide a competitive edge over existing GLP-1 receptor agonists, particularly if it demonstrates superior efficacy and safety profiles. Viking Therapeutics, Inc. should prepare for potential partnerships or licensing opportunities based on trial outcomes, as well as consider strategies for market entry and positioning against established players in the obesity treatment landscape.